MS and Demyelinating Disorders

In mixed-effect analyses adjusting for multiple cofounders, changes in inflammatory gene expression correlated inversely with changes in patient-reported stress, loneliness, hair cortisol, and aspects of interoceptive awareness.

Investigators observed significant correlations between processing speed and arterial stiffness among patients with multiple sclerosis, but not in healthy controls.

Over the 96-week treatment period, ublituximab-treated patients outperformed teriflunomide-treated patients on several domains of the Fatigue Impact Scale.

Despite similar proportion of females and ever-smokers, age of onset of multiple sclerosis was significantly earlier for Latinx patients compared with White non-Latinx individuals.

Investigators observed significant decreases in Modified Fatigue Impact Scale and Fatigue Severity Scale with the low-fat diet in relation to controls.

In this episode of MEDcast, expert neurologists delve into anti-CD20 disease-modifying therapies (DMTs) in MS. They assess the correlation between clinical observations and immunological processes in MS patients, and also examine the role of the Epstein Barr virus in MS. [LISTEN TIME: 48 minutes]

Experts in neurology provide insight on challenges that arise with the use of generic DMTs in RRMS treatment, such as cost to the patient.

Ahmed Zayed Obeidat MD, PhD; Ravi Dukkipati, MD; and Gabriel Pardo, MD, FAAN, comment on the use of generic DMTs in the treatment of RRMS, highlighting efficacy and safety data as well as level of equivalence to brand name treatments.

Tiffany Braley, MD, MS, associate professor of neurology, University of Michigan, provided insight on the challenges of fatigue in multiple sclerosis, and where research efforts should be directed to.

In recognition of World MS Day, Meghan Beier, PhD, MA, a health and rehabilitation psychologist at the Rowan Center for Behavioral Medicine, discussed the effects of multiple sclerosis (MS) on cognitive function.

The research, which highlighted stressors occurring in both childhood and adult stages contributing to MS disability, could inform conversations regarding stress reduction techniques for patients with MS.

In recognition of World MS Day, the health and rehabilitation psychologist at the Rowan Center for Behavioral Medicine discussed types of interventions for managing cognitive changes in patients with multiple sclerosis. [WATCH TIME: 5 minutes]

Kathy Zackowski, PhD, OTR, associate vice president of research at the National MS Society, provided insight on the ongoing efforts to treat progressive MS, including strategies to develop remyelinating treatments.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer disease and dementia.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 26, 2023.

The head of CRCSEP and coordinator of the Neurosciences Research Unit at Paris City University discussed the positive results of teriflunomide in treating radiologically isolated syndrome, a preclinical stage of multiple sclerosis. [WATCH TIME: 4 minutes]

Expert neurologists discuss treatment options for a patient with comorbid autoimmune diseases, relapsing/remitting multiple sclerosis, and psoriasis.

Ravi Dukkipati, MD, and Gabriel Pardo, MD, FAAN, review the use of rituximab and other disease-modifying therapies in a patient with an established diagnosis of relapsing/remitting multiple sclerosis.

Clinically relevant effect sizes were observed, with those in the highest Dietary Inflammatory Index quartile having relapse risk 2.45 times higher than those in the lowest quartile.

Findings showed that greater average daily step count was significantly correlated with greater C2-C3 spinal cord gray matter areas, total cord area, and cortical gray matter volume.

The senior academic at the University of Sydney provided perspective on the role of CNM-Au8 in MS among a crowded treatment landscape, and the need for adjuvant treatments that address lingering lesion burden. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep and sleep disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 19, 2023.

The assistant professor of neurology at the University of North Carolina at Chapel Hill discussed the importance of recognizing disability as part of diversity in neurology, emphasizing the need for inclusive communication and accessibility for disabled patients. [WATCH TIME: 10 minutes]

Anand Patel, MD, CPI, chief medical officer at Conquest Research, discussed a phase 2 study that investigated the efficacy and safety of LX9211, an oral medication targeting neuropathic pain.

Neurological rehabilitation, or neurorehabilitation, can be described as the use of rehabilitation interventions to improve or maintain function and quality of life in the context of neurological conditions.

Bruce Hughes, MD, comments on the current use and access to biomarkers in MS management, as well as sharing how NfL is being used in clinical practice presently.

An expert neurologist discusses pNfL being utilized outside of clinical trials and implemented into clinical practice for the treatment of MS.